MicroSectors Gold Miners 3X Leveraged ETN (ARCA: GDXU)

Latest news for MicroSectors Gold Miners 3X Leveraged ETN (ARCA:GDXU)

ETN offers investors a return based on changes in the level of the S-Network MicroSectors Gold Miners Index, compounded daily, before taking into account fees. Each ETN has a specified leverage factor that is reset daily.

MicroSectors Gold Miners 3X Leveraged ETN

News

Specialty ETFs

New ETFs

Commodities

Markets

ETFs

DUST

Market Vectors ETF Trust Market Vectors Gold Miners

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

GDXD

GDXJ

GDXU

JDST

JNUG

NUGT

 

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Prior to March, traders who wanted to go long or short gold miners with 3x leverage had a number of options. 

The 3x Gold Trade Is Back

Long Ideas

Short Ideas

Trading Ideas

GOLD

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

New 3X Leveraged Gold Miners ETNs Begin Trading

Sector ETFs

FNGS

FNGU

Gold is hot this year and the miners are even hotter, a scenario bringing more light to the various leveraged exchange traded products that provide access to the companies extracting gold from the earth.

New ETNs Bring Leverage, Spice To Gold Miners

HC Wainwright &amp; Co. analyst Robert Burns upgrades Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) from Neutral to Buy and announces $5 price target.

Upgrades

Price Target

Analyst Ratings

PRLD

HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target

B. Riley Securities analyst Madison El-Saadi initiates coverage on WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy rating and announces Price Target of $11.

Initiation

B. Riley Securities Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $11

Legal

General

TUSK

Cobra Acquisitions, A Subsidiary Of Mammoth Energy Services, Announced That The Previously Disclosed Settlement Agreement With The Puerto Rico Electric Power Authority Was Approved By The Title III Court, PREPA Required To Pay Cobra $150M Within Ten Business Days

<ul>
<li>One program aims to identify novel Aramchol-based drug combinations to overcome resistance to standard-of-care oncological treatments for patients with advanced colorectal and hepatic cancers.&nbsp;</li>
<li>Another program aims to unravel new mechanisms of action that will allow the development of a novel Aramchol-based drug combination targeting cardiac fibrosis, or scarring of the heart, which occurs in many cardiovascular diseases that can lead to heart dysfunction and failure.&nbsp;</li>
<li>The Company plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.</li>
</ul>

Biotech

Health Care

GLMD

Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years

B. Riley Securities initiates coverage on Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy rating and announces Price Target of $33.

CNTA

B. Riley Securities Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $33

COEP

Coeptis Therapeutics Receives Notification Letter From Nasdaq Hearings Panel Granting Its Request For Continued Listing Through January 15, 2025

SYTA

Siyata Mobile Announced That Its SD7 Handsets And VK7 Vehicle Kits Were Purchased And Deployed By A New Customer, Trans-west Security Systems

Raymond James analyst Stephen Laws upgrades Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) from Market Perform to Outperform and announces $34 price target.

SAFE

Raymond James Upgrades Safehold to Outperform, Announces $34 Price Target

SpaceX CEO Elon Musk said on Thursday that the rocket manufacturing company intends to <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights">offer a trip to Mars</a> to anyone who volunteers in the future but warned that the journey might be uncomfortable.
What Happened: &#8220;In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go&#8230;&#8221; Musk wrote on social media platform X in response to former European Union Commissioner Thierry Breton with whom he has a history of sparring now and then.
However, the journey to Mars, Musk warned, will be like a &#8220;long sea voyage.&#8221;
&#8220;&#8230;.it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure!&#8221; Musk said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">In all seriousness, SpaceX hopes to offer travel to Mars to anyone who wants to go, bearing in mind that it will be like a long sea voyage in centuries past – dangerous and uncomfortable, but great adventure! Becoming multiplanetary ensures the long-term survival of life.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1836705091446853687?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk aims to take humans to Mars with SpaceX&#8217;s Starship launch vehicle in an attempt to &#8220;make life multi-planetary.&#8221; Musk has previously even envisioned a self-sustaining city on Mars called Terminus.
Why It Matters: Earlier this month, Musk said the first Starships will <a href="https://www.benzinga.com/news/24/07/39567836/spacex-ceo-elon-musk-picks-terminus-for-mars-first-starship-enabled-city-after-just-4-test-flights" target="_blank" rel="noreferrer noopener">head to Mars in two years</a> once the next Earth-Mars transfer window opens.
The first launches to Mars in 2026, Musk then said, will not have a crew onboard and will be aimed at testing the flight's ability to land intact on Mars.
"If those landings go well, then the first crewed flights to Mars will be in 4 years," Musk wrote, pegging the first crewed Starship flights to the neighboring planet for 2028. A self-sustaining city, he said, should be ready in about 20 years. 
Starship, however, is still under development and undergoing test flights. It was last launched in June and the company is <a href="https://www.benzinga.com/news/24/09/40932353/spacex-continues-to-prepare-for-future-starship-flights-despite-delays-in-faa-launch-clearance-elon">now awaiting the green light </a>from the Federal Aviation Administration for its fifth flight test. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40934031/teamsters-opts-to-not-endorse-either-harris-or-trump-for-upcoming-presidential-elections-citing-fail">Teamsters Opts To Not Endorse Either Harris Or Trump For Upcoming Presidential Elections, Citing Failure To Secure Pledges Of Non-Interference In Union Campaigns</a></li>
</ul>
Image generated using Midjourney and official SpaceX photos on Flickr

SPACE

Tech

SpaceX CEO Elon Musk Says Anyone Can Go To Mars With SpaceX But Journey Would Be Like A 'Long Sea Voyage In Centuries Past'

HC Wainwright &amp; Co. analyst Arthur He reiterates Satellos Bioscience (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MSCL#TSX">MSCL</a>) with a Buy and maintains C$1.2 price target.

Reiteration

TSX:MSCL

HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains C$1.2 Price Target

ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.&nbsp;

ACET

Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases

Offerings

Murphy Oil Intends To Offer $600M Of Senior Notes Due 2032

Ahead of the 2024 presidential election, Elon Musk has thrown his support behind Donald Trump, while his employees are reportedly largely backing Kamala Harris, according to recent data.
What Happened: According to OpenSecrets, employees at Tesla Inc. have contributed $42,824 to Harris&#8217; campaign, compared to $24,840 for Trump. Workers at SpaceX have donated $34,526 to Harris, while only $7,652 has gone to Trump. At X, formerly Twitter, employees have given $13,213 to Harris and less than $500 to Trump, Reuters reported on Thursday.
These figures, though relatively small, highlight a political divide between Musk and his workforce. Musk, the world&#8217;s richest man, has promoted Trump on X and criticized left-leaning ideologies as a &#8220;woke-mind virus.&#8221; He did not respond to requests for comment. In 2020, Musk supported President Joe Biden but has since shifted rightward.
Trump has promised to appoint Musk to lead a government efficiency commission if he wins the Nov. 5 election. The OpenSecrets data includes donations from employees, owners, and their immediate family members, as companies themselves cannot donate to federal campaigns.
See Also: <a href="https://www.benzinga.com/news/24/09/40899012/elon-musk-reacts-after-trump-campaign-releases-over-50-examples-of-democrats-rhetoric-that-inspired?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Trump Campaign Releases Over 50 Examples of Democrats&#8217; Rhetoric That &#8216;Inspired Assassination Attempt&#8217;</a>
Many of Musk&#8217;s employees are based in California, a Democratic stronghold, noted Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, a Tesla shareholder and X investor. In July, Musk announced plans to move X and SpaceX headquarters to Texas due to a California gender-identity law, which he called the &#8220;last straw.&#8221; 
Tesla and X have yet to respond to Benzinga&#8217;s queries.
Why It Matters: Musk&#8217;s political stance has evolved significantly over the years. In August, Musk explained his <a href="https://www.benzinga.com/news/24/08/40329702/elon-musk-who-once-queued-for-6-hours-to-shake-obamas-hand-explains-why-hes-now-supporting-trump-my">support for Trump</a>, stating that his track record has been moderate and he has not been particularly political in the past. He revealed this during a conversation with Trump, touching on various topics from immigration to electric vehicles. 
In September, Musk commented on a debate between Trump and Harris, expressing <a href="https://www.benzinga.com/news/24/09/40808912/elon-musk-says-kamala-harris-exceeded-most-peoples-expectations-but-debate-hosts-were-unfair-to-trum">dissatisfaction with the debate hosts</a> and raising concerns about the lack of discussion on the national debt crisis. He also mentioned that Harris exceeded most people&#8217;s expectations during the debate.
Recently, Musk faced backlash for a <a href="https://www.benzinga.com/news/24/09/40890277/elon-musk-says-his-now-deleted-controversial-post-after-latest-trump-assassination-which-was-labeled">controversial post on X</a>, which he later deleted. The post questioned why no one was attempting to assassinate President Joe Biden or Harris, following an assassination attempt on Trump. The White House labeled the post as &#8220;irresponsible.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

TSLA

While Elon Musk Backs Trump For The White House, His Teams At Tesla, X And SpaceX Are Supporting Kamala Harris: Employees Have Reportedly Donated Over $90K To Vice President's Campaign

Raymond James analyst Stephen Laws downgrades NexPoint Real Est Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) from Strong Buy to Market Perform.

Downgrades

NREF

Raymond James Downgrades NexPoint Real Est Finance to Market Perform

This significant grant will fund a key research study over the next several years, advancing preclinical and ultimately, clinical studies of intranasal anti-CD3 as a potential treatment for this devastating neurodegenerative condition.

Financing

TLSA

Tiziana Life Sciences Announced The National Institutes Of Health Have Awarded A $4M Grant To Study Nasal Anti-CD3 For Alzheimer's Disease

Confirmed overall response rate (ORR) was&nbsp;37.5%&nbsp;for pelareorep + paclitaxel and&nbsp;13.3%&nbsp;for paclitaxel.&nbsp;As previously reported, ORRs at week 16 (the trial&#39;s primary endpoint) in the pelareorep + paclitaxel and paclitaxel monotherapy cohorts were&nbsp;31%&nbsp;and&nbsp;20%, respectively.
&quot;The fact that the median overall survival was not reached because more than half the patients were still alive at the end of the study is a remarkable achievement for us,&quot; said&nbsp;Wayne Pisano, Interim CEO and Chair of Oncolytics&#39; Board of Directors.
&nbsp;

ONCY

Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study

Raymond James analyst Stephen Laws downgrades Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) from Outperform to Market Perform.

Raymond James Downgrades Lument Finance Trust to Market Perform

SLRN

Acelyrin Announced That Results From Its Global Phase 3 Trial Of Izokibep In Moderate-to-severe Hidradenitis Suppurativa Patients Will Be Shared At The 2024 European Academy Of Dermatology And Venereology

Raymond James analyst James Rollyson initiates coverage on Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announces Price Target of $14.

Raymond James Initiates Coverage On Helix Energy Solns Gr with Strong Buy Rating, Announces Price Target of $14

<ul>
<li>In a Phase 1 in healthy subjects, EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF).</li>
<li>CIRRUS-HCM single-dose trial of EDG-7500 in obstructive HCM demonstrated robust left ventricular outflow tract (LVOT) gradient reductions without meaningful changes in LVEF.</li>
<li>Company announced dosing of first patients in CIRRUS-HCM 28-day trial.</li>
</ul>

EWTX

Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

MicroSectors Gold Miners 3X Leveraged ETN

News

Latest news for MicroSectors Gold Miners 3X Leveraged ETN (ARCA:GDXU)

Monday, October 31, 2022

Thursday, December 10, 2020

Tuesday, December 08, 2020

Thursday, December 03, 2020